# Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma

> **NCT00730444** · — · APPROVED_FOR_MARKETING · sponsor: **GE Healthcare**

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Iobenguane I 123 Injection

## Key facts

- **NCT ID:** NCT00730444
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00730444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00730444, "Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00730444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*